Recruiting studies: Relapsed Or Refractory Peripheral T Cell Lymphoma Ptcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Phase 2 · 6 location(s) · University of Virginia · NCT04747236 A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823 Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724 RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
Phase 2 · 1 location(s) · Xianmin Song, MD · NCT06468267 Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · 34 location(s) · Corvus Pharmaceuticals, Inc. · NCT06561048 Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Phase 1 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT05079282 CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/Phase 2 · 4 location(s) · Beijing GoBroad Hospital · NCT06925464 CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/Phase 2 · 3 location(s) · Beijing GoBroad Hospital · NCT07022964 A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07055477 To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07143929 Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06874946 A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Phase 1/Phase 2 · 20 location(s) · The Lymphoma Academic Research Organisation · NCT07018752 A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/Phase 2 · 1 location(s) · Genfleet Therapeutics (Shanghai) Inc. · NCT05934513 Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06810778

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.